Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, has scheduled its fourth quarter and full year 2024 financial results announcement for March 5, 2025, after market close.
The company will host a conference call and webcast at 4:30 pm Eastern Time on the same day, where management will discuss the financial results and provide a corporate update. Investors can access the webcast live and replay through Zymeworks' investor relations website.
Zymeworks Inc. (Nasdaq: ZYME), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di bioterapici multifunzionali per il cancro, l'infiammazione e le malattie autoimmuni, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 5 marzo 2025, dopo la chiusura del mercato.
L'azienda ospiterà una conferenza telefonica e un webcast alle 16:30 ora orientale dello stesso giorno, durante il quale la direzione discuterà i risultati finanziari e fornirà un aggiornamento aziendale. Gli investitori potranno accedere al webcast in diretta e rivederlo tramite il sito web delle relazioni con gli investitori di Zymeworks.
Zymeworks Inc. (Nasdaq: ZYME), una empresa biotecnológica en etapa clínica centrada en el desarrollo de bioterapéuticos multifuncionales para el cáncer, la inflamación y enfermedades autoinmunes, ha programado el anuncio de resultados financieros del cuarto trimestre y del año completo 2024 para el 5 de marzo de 2025, después del cierre del mercado.
La compañía llevará a cabo una conferencia telefónica y un webcast a las 4:30 p.m. hora del Este el mismo día, donde la dirección discutirá los resultados financieros y proporcionará una actualización corporativa. Los inversores podrán acceder al webcast en vivo y volver a verlo a través del sitio web de relaciones con inversores de Zymeworks.
Zymeworks Inc. (Nasdaq: ZYME)는 암, 염증 및 자가면역 질환을 위한 다기능 생물의약품 개발에 집중하는 임상 단계의 생명공학 회사로, 2024년 4분기 및 연간 재무 실적 발표를 2025년 3월 5일, 시장 마감 후로 예정했습니다.
회사는 같은 날 동부 표준시 오후 4시 30분에 컨퍼런스 콜 및 웹캐스트를 개최하며, 경영진이 재무 실적을 논의하고 기업 업데이트를 제공할 예정입니다. 투자자들은 Zymeworks의 투자자 관계 웹사이트를 통해 웹캐스트를 실시간으로 보고 재생할 수 있습니다.
Zymeworks Inc. (Nasdaq: ZYME), une entreprise biopharmaceutique en phase clinique axée sur le développement de biothérapeutiques multifonctionnels pour le cancer, l'inflammation et les maladies auto-immunes, a programmé l'annonce des résultats financiers du quatrième trimestre et de l'année 2024 pour le 5 mars 2025, après la fermeture du marché.
L'entreprise organisera une conférence téléphonique et un webinaire à 16h30, heure de l'Est le même jour, où la direction discutera des résultats financiers et fournira une mise à jour de l'entreprise. Les investisseurs peuvent accéder au webinaire en direct et le revoir via le site web des relations investisseurs de Zymeworks.
Zymeworks Inc. (Nasdaq: ZYME), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung multifunktionaler Biotherapeutika für Krebs, Entzündungen und Autoimmunerkrankungen konzentriert, hat die Ankündigung der finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 5. März 2025 nach Börsenschluss angesetzt.
Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast ausrichten, in dem das Management die finanziellen Ergebnisse besprechen und ein Unternehmensupdate geben wird. Investoren können den Webcast live verfolgen und über die Investor-Relations-Website von Zymeworks erneut ansehen.
- None.
- None.
VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its fourth quarter and full year 2024 financial results after market close on March 5, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 5, 2025 at 4:30 pm Eastern Time (ET).
The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera® is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with investigational new drug applications for ZW220 and ZW251 planned for 2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
FAQ
When will Zymeworks (ZYME) release its Q4 and full year 2024 earnings?
What time is Zymeworks (ZYME) Q4 2024 earnings call?
Where can I access Zymeworks (ZYME) Q4 2024 earnings webcast?
What areas does Zymeworks (ZYME) focus on for its biotherapeutics development?
